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Sir,
Vlahovic et al, provided evidence of effectiveness of Imatinib
treatment in PDGFRB-overexpressing human lung adenocarcinoma
xenografts grown in nude mice. In this preclinical model,
the effectiveness of the drug is related to decrease in interstitial
fluid pressure (IFP), decrease of phosphorylated PDGFRB and
VEGF expression and improvement of oxygenation (Vlahovic
et al, 2006). Furthermore, according to the working hypothesis
that inhibition of PDGFRB decreases IFP and improves first-line
therapy through drug uptake increase (Pietras, 2004), a clinical
trial investigating the role of Imatinib as an adjuvant to
chemotherapy is ongoing in stromal PDGFRB expressing
non-small-cell lung cancer (NSCLC) (Vlahovic et al, 2006). Here
we demonstrate that Imatinib in adjunction to chemotherapy
may also be effective in a lung adenocarcinoma made up of
tumour cells expressing Imatinib-sensitive deregulated genes
such as PDGFRA, PDGFRB and c-Kit in presence of EGFR
and HER-2/neu amplification lacking any evidence of protein
expression.
An NSCLC, corresponding to a poorly differentiated adeno-
carcinoma, was diagnosed 1 month after starting treatment with
Imatinib for a locally advanced sacral chordoma in a 64-year-old
male patient. The chordoma expressed an activated PDGFRB
(detected by immunoprecipitation/Western blotting (IP/WB)
experiments) and the cognate ligand (by RT–PCR), findings
consistent with the presence of an autocrine/paracrine loop (Casali
et al, 2004). At the time the second primary was detected, the
chordoma was showing a weak dimensional response to Imatinib.
The lung carcinoma was initially surgically treated, but relapsed
to the mediastinum 17 months later, when the chordoma seemed
to undergo slight secondary progression on Imatinib. Soon after
stopping Imatinib, the patient received cisplatin plus vinorelbine
with concomitant radiotherapy and, four months later, at the end
of chemo-radiotherapy, CT and PET revealed an optimal complete
radiological and functional response of lung tumour. Surprisingly,
given the poor chemosensitivity of chordomas, there was also an
initial minor response of the sacral tumour, which was lost soon
after, but then was restored with the resumption of Imatinib (the
plan was to reintroduce the latter in combination with cisplatin,
but renal function did not allow it).
The primary lung tumour was investigated in addition to
FISH analysis, by IHC, IP/WB and DNA sequencing (after the
informed consent of the patient) (Figure 1). Cumulatively,
the FISH findings were consistent with a high degree of genetic
instability showing high polisomy of PDGFRA, PDGFRB and
c-Kit genes, coupled with activation (phosphorylation) of all
the three receptors at IP/WB analysis and positivity at IHC
(anti-PDGFRA sc-338 and anti-PDGFRB sc-339, Santa Cruz
Biotechnology, CA, USA; anti-CD117 A4502, Dako, Carpinteria,
CA, USA), as well as, as already anticipated, EGFR and HER-2/neu
amplification coupled with null IHC (Dako) and biochemical
analysis. Molecular analysis performed for investigating the
mutation hot-spots of RTK genes excluded the presence of any
activating mutation.
Finally, FISH analysis performed on the chordoma biopsy
obtained during surgery for adenocarcinoma showed a dysomic
pattern of all the investigated RTK genes.
The present findings imply firstly that the lung adenocarcinoma
tumoral cells, in addition to EGFR and HER-2/neu gene deregula-
tion, successfully treated with EGFR family inhibitors (Bunn et al,
2006), may harbour gene amplification and phosphorylation of
Imatinib-sensitive RTKs, and so the spectrum of deregulated RTK
genes in NSCLC is wider than believed. Secondly that, although
supported by different mechanisms (an autocrine/paracrine
activation loop of PDGFRA, PDGFRB and KIT in chordoma
(Tamborini et al, 2006) and a gene gain in lung cancer), the two
tumours carried the same Imatinib-sensitive deregulated genes
and are thus expected to be sensitive to the same drug. The
sequence of clinical events is hard to interpret but, together with
the biomolecular findings, what was observed strongly supports
the possibility that the efficacy of the chemotherapy against the
NSCLC may have benefited from Imatinib, and the efficacy of
Imatinib against chordoma may have benefited from the
chemotherapy. Cumulatively, all these findings give further
support to the ongoing clinical trial in selected patients with
NSCLC (Vlahovic et al, 2006) and, in particular, for PDGFRB, they
point out that this receptor is a multifaced player that through
different mechanisms may affect the treatment response of both
standard treatments and target therapies.*Correspondence: Dr S Pilotti; E-mail: silvana.pilotti@istitutotumori.mi.it
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Figure 1 Upper panel. FISH analysis. A probe mix for PDGFRB (BAC clone RP11-368O19) (in green)/a locus specific in 5p (in red), PDGFRA (BAC clone
RP11-231C18) (in green)/Cep4 ( in red) (Vysis) and c-Kit (BAC clone RP11-586A2 (in green)/Cep4 (in red) (Vysis), respectively, was employed to detect
gene status for the receptors. A condition of high polisomy was detected for PDGFRB, PDGFRA and c-Kit. Lower panel. Immunoprecipitations/Western blot
analysis. Equal amounts of total protein extracts (1 mg) were immunoprecipitated using the specified antibodies (PDGFRB sc 432, Santa Cruz Biotechnology;
PDGFRA 07–276, Upstate, Charlottesville, VA, USA and KIT Ab-3, clone K45, Neomarkers, Fremont, CA, USA) subsequently blotted to a membrane and
incubated first with anti p-Tyr antibody (clone 4G, Upstate) and then with antibodies for the specified receptors. As positive controls, for PDGFRA and
PDGFRB, an NIH3T3 cell line was employed, whereas for KIT a D559 cell line expressing a constitutively activated KIT receptor was used.
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